Characterization and Support for Neurodevelopmental Disorders Associated With Congenital Heart Defects
CATAMARAN - Pediatrics : Characterization and Support for Neurodevelopmental Disorders Associated With Congenital Heart Defects
Nantes University Hospital
1,206 participants
Jul 8, 2024
INTERVENTIONAL
Conditions
Summary
The leading cause of birth defects, Congenital Heart Defects (CHD) affect 12 million people worldwide and 41,000 newborns/year in Europe. It's a major cause of life-long morbidity and mortality, and a crucial public health issue. More than 50% of childs born with critical CHD will develop Neurodevelopmental Disorders (NDs), requiring specific care and impairing quality of life. NDs corresponds to early and lasting disturbances in cognitive, affective and behavioral development, linked to abnormalities in brain development. They are heterogeneous, affecting language, learning, motor skills, intellectual efficiency, social cognition, attention, memory and executive functions, and are associated with psychosocial difficulties (adaptive behavior, social interactions). This hidden handicap is the main long-term sequels of CHD, even before cardiovascular sequels, in individuals who often underwent multiple heart operations in early childhood. NDs concern not only complex CHD, but also simple CHD repaired in childhood and considered cured. The origin of TND associated with CHD is largely unknown. To date, few genetic or environmental causes have been clearly identified, but recent work has suggested that a common origin may link cardiac malformation and neurodevelopmental abnormality. The CATAMARAN - Pediatrics project is designed to detect potential neurodevelopmental delays associated with CHD as early as age 3, and to identify individual susceptibility factors involved in the occurrence of NDs in CHD children.
Eligibility
Inclusion Criteria6
- Child (aged 3 to 11) with critical MCC operated on for heart surgery during the first three months of life
- Parents and child affiliated with or benefiting from a social security or similar scheme
- Parents' and child's good understanding of the French language
- Free, informed and written consent of both parents for themselves and for the child
- Free, informed and written consent of the child aged 6 and over
- Biological parents
Exclusion Criteria2
- Genetic anomaly or malformative syndrome associated with neurodevelopmental abnormalities, identified prior to inclusion
- Neurodevelopmental assessment not practicable
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
An EDTA blood sample will be taken from the children and their two parents. Sample volume will be 2 x 3mL.
The children will be seen by a neuropsychologist, who will then determine whether or not they have neurodevelopmental disorders.
The children will be seen by a multidisciplinary team (including a neuropsychologist), who will then determine whether or not they have neurodevelopmental disorders.
Parents' parental stress will be assessed using the Parental Stress Index (PSI) questionnaire.
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06442592